July 11, 2021
Pakistan has earned $10 million by conducting first-ever Phase-III clinical trials for the single-dose Chinese Covid-19 vaccine CanSino Bio at five leading public and private health facilities in the country, and now the National Institute of Health (NIH) is going to earn 30 million dollars within a year by co-manufacturing the same vaccine after technology transfer from China, officials said on Saturday.
“Phase-III clinical trials of the CanSino Biologics single-dose Covid-19 were the first-ever such trials conducted in Pakistan and we earned $10 million by conducting these trials at five centres in Karachi, Lahore and Islamabad. Now we are being approached by companies from the UK, Korea and Japan, as well as from China for conducting Phase-III clinical trials of several more vaccines, which can earn us huge revenue and foreign exchange,” said Major General Aamer Ikram, executive director of the National Institute of Health Islamabad, at a health conference in
WHO support strengthens testing capacity for COVID-19 in Pakistan
Format
27 June 2021 – Dr Palitha Mahipala, WHO Representative in Pakistan, handed over a PCR machine and biosafety cabinet for Mianwali district to Major General Aamer Ikram, Executive Director, National Institute of Health in Islamabad, during an event at the WHO country office in Islamabad. WHO has so far delivered 32 PCR machines and other equipment to improve testing capacity for COVID-19 testing in Pakistan. The equipment aims to enhance laboratory testing capacity for COVID-19. WHO in Pakistan is collaborating with the National Institute of Health to strengthen testing capacity and genomic surveillance for SARS-CoV2 variants.
Pakistan to locally manufacture vaccine with China s assistance chinadaily.com.cn | Updated: 2021-04-16 14:28 A worker checks a container of CanSino COVID-19 vaccines at Islamabad International Airport in Islamabad, Pakistan, on March 30, 2021. [Photo/Xinhua]
Pakistan will locally produce the CanSino COVID-19 vaccine with the help of China, Turkey s Anadolu Agency reported on Wednesday.
China s single-dose CanSinoBio vaccine will be prepared in Pakistan locally soon , said Major-General Aamer Ikram, the head of the country s state-run National Institute of Health.
Beijing has agreed to transfer the technology for the vaccine to Islamabad, and the raw material of the vaccine will arrive in Pakistan by the end of April, he said.
National
April 16, 2021
Islamabad: National Institute of Health (NIH) has revealed that it is working to develop a single-dose coronavirus vaccine. Our team is ready to undertake this task, while a Chinese team is already here to oversee the exercise, NIH executive director Major General Aamer Ikram told the National Assembly standing committee on national health services here.
He said the NIH had carried out the clinical trial of Chinese COVID-19 vaccine CanSinoBio placing the country among the first few to do so. The NIH chief said China had been formally asked for the transfer of the vaccine technology and the raw material for the vaccine would reach the country shortly. He said the process for manufacturing the COVID-19 vaccine would begin following the imminent restoration of the relevant NIH plant, which was closed a few years ago.
Work on single-dose corona vaccine underway thenews.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenews.com.pk Daily Mail and Mail on Sunday newspapers.